Table 2 Features of the patients before the second [68Â Ga]Ga-PSMA-11 PET/CT images
From: Systemic therapy response evaluation in prostate carcinoma with [68Ga]Ga-PSMA-11 PET/CT
Feature | Â | Â | Total |
|---|---|---|---|
Castration resistance | Sensitive | 20 (40%) | 50 (100%) |
Resistant | 30 (60%) | ||
Received treatment | First-line hormone therapy | 17 (34%) | 50 (100%) |
Docetaxel | 21 (42%) | ||
Cabazitaxel | 3 (6%) | ||
Enzalutamide | 3 (6%) | ||
Abiraterone | 3 (6%) | ||
[177Lu]Lu-PSMA-617 | 3 (6%) | ||
Treatment group | Antiandrogenic | 23 (46%) | 50 (100%) |
Chemotherapeutic | 24 (48%) | ||
Radionuclide | 3 (6%) |